Randomized studies of GO in previously untreated AML
ADE indicates cytarabine/daunorubicin/etoposide; ALFA, Acute Leukemia French Association; CI, confidence interval; DA, daunorubicin/cytarabine; DClo, daunorubicin/clofarabine; DFS, disease-free survival; EFS, event-free survival; FLAG-IDA, fludarabine/cytarabine/granulocyte colony-stimulating factor/idarubicin; GOELAMS, Groupe Ouest Est d'Etude des Leucémies aiguës et Autres Maladies du Sang; HR, high risk; IR, intermediate risk; LRF, Leukaemia Research Fund; MA, mitoxantrone/cytarabine; MRC, Medical Research Council; NCRI, National Cancer Research Institute; OR, odds ratio; ORR, overall response rate (CR + CRi); OS, overall survival; RR, relapse risk; TRM, treatment-related mortality.
* Daunorubicin was used at 60 mg/m2/d in the control arm and 45 mg/m2/d in the GO arm.
